Research Agreement under which WED conducts research studies on targeted gene therapy and Elanco US pays up to $4 million to fund the research in exchange for certain intellectual property rights
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Jeffrey Simmons
Also a director
PRESIDENT, CEO AND DIRECTOR
Title from the Form 4 dated Oct 30, 2026
|
58 | Not stated | Not stated | $14,925,756 | |
|
Robert VanHimbergen
Executive Vice President and Chief Financial Officer
|
49 |
Since 2025
1 year
|
2025 | $4,661,304 | |
|
James Meer
Senior Vice President, Chief Accounting Officer
|
56 | Not stated | 2018 | Not reported | |
|
Shiv O’Neill
GC AND CORP SEC
Title from the Form 4 dated Aug 18, 2026
|
52 | Not stated | Not stated | Not reported | |
|
Jamie Preston
EVP, Chief People Officer
Title from the Form 3 dated Nov 3, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Grace McArdle
Executive Vice President, Manufacturing and Quality
|
47 |
Since 2023
3 years
|
Not stated | Not reported | |
|
José Manuel Correia de Simas
Executive Vice President, U.S. Farm Animal Business
|
58 |
Since 2020
6 years
|
2000 | Not reported | |
|
David Kinard
SEE REMARKS
Title from the Form 4 dated Jul 1, 2026
|
59 | Not stated | Not stated | Not reported | |
|
Rajeev (Bobby) Modi
SEE REMARKS
Title from the Form 4 dated Oct 30, 2026
|
45 | Not stated | 2022 | Not reported | |
|
Timothy J Bettington
SEE REMARKS
Title from the Form 4 dated Oct 15, 2026
|
Not stated | Not stated | Not stated | $2,583,505 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Research Agreement under which WED conducts research studies on targeted gene therapy and Elanco US pays up to $4 million to fund the research in exchange for certain intellectual property rights
Loading...